1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,120 | 0,178 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12. | Cantargia Publishes Strong Preclinical Effects and Clinical Monotherapy Results on Nadunolimab in Pancreatic Cancer in Journal for Immunotherapy of Cancer | 199 | ACCESSWIRE | LUND, SE / ACCESSWIRE / December 18, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of preclinical and clinical results using the IL1RAP... ► Artikel lesen | |
| 11.12. | Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational Results on Nadunolimab Treatment in Advanced Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium | 229 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / December 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported updated results from the phase 1b study in 15 advanced triple negative... ► Artikel lesen | |
| 02.12. | Extraordinary General Meeting in Cantargia AB | 163 | ACCESSWIRE | LUND, SE / ACCESSWIRE / December 02, 2024 / Cantargia (STO:CANTA) Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase... ► Artikel lesen | |
| 02.12. | Cantargia AB: Extraordinary general meeting in Cantargia AB (publ) | 219 | GlobeNewswire (Europe) | Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase the company's share capital through the issuance of new shares... ► Artikel lesen | |
| 02.12. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.12.2024 | 174 | Xetra Newsboard | Das Instrument F1S AU000000OAR8 OAR RESOURCES LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 02.12.2024 und ex Kapitalmassnahme am 03.12.2024 The instrument F1S AU000000OAR8 OAR RESOURCES LTD. EQUITY... ► Artikel lesen | |
| 29.11. | Cantargia Expands the CAN10 Phase 1 Clinical Program Building on Positive Results | 222 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / November 29, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study... ► Artikel lesen | |
| 15.11. | Cantargia Publishes Interim Report for Third Quarter 2024 | 195 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / November 15, 2024 / Cantargia (STO:CANTA) Cantargia AB's ("Cantargia") interim report for the period January until September 2024 is now available on the company's web page... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 13.11. | Cantargia Presents Nomination Committee Ahead of 2025 AGM | 182 | ACCESSWIRE | LUND, SE / ACCESSWIRE / November 13, 2024 / Cantargia (STO:CANTA) Cantargia AB (publ) hereby provides notification that the Nomination Committee (NC) has been appointed ahead of the 2025 Annual General... ► Artikel lesen | |
| 11.11. | Cantargia Results Showing Efficacy of CAN10 in Models of Myocarditis Published in Circulation: Heart Failure | 492 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / November 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced the publication of CAN10 results in disease models of myocarditis... ► Artikel lesen | |
| 06.11. | Notice of extraordinary general meeting in Cantargia AB | 239 | ACCESSWIRE | LUND, SE / ACCESSWIRE / November 6, 2024 / Cantargia (STO:CANTA) The shareholders of Cantargia AB (publ) are invited to the extraordinary general meeting on Monday, 2 December 2024, at 10.00 CET at... ► Artikel lesen | |
| 05.11. | Cantargia Presents Promising Preclinical Results on Nadunolimab With Antibody-Drug Conjugates at Major Immuno-Oncology Conference | 181 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / November 05, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported preclinical results on potential synergism between nadunolimab and... ► Artikel lesen | |
| 01.11. | Invitation to Presentation of Cantargia's Interim Report January - September 2024 | 230 | ACCESSWIRE | LUND, SE / ACCESSWIRE / November 01, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) invites investors, analysts and the press to a presentation of the interim report for... ► Artikel lesen | |
| 28.10. | Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies | 296 | ACCESSWIRE | LUND, SE / ACCESSWIRE / October 28, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced new clinical results from two nadunolimab combination therapy trials... ► Artikel lesen | |
| 11.10. | Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study | 267 | ACCESSWIRE | LUND, SE / ACCESSWIRE / October 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced new results from the CAN10 phase 1 clinical study. All nine groups... ► Artikel lesen | |
| 10.10. | Cantargia's Strong Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab Published in Clinical Cancer Research | 337 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / October 10, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of the results using nadunolimab (CAN04) combination... ► Artikel lesen | |
| 25.09. | Cantargia Presents New Results at EADV 2024 Highlighting the Potential of CAN10 Treatment in Dermatology | 255 | ACCESSWIRE | LUND, SE / ACCESSWIRE / September 25, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from preclinical experiments showing the high potential of the... ► Artikel lesen | |
| 14.09. | Cantargia Presents Positive Results at ESMO Congress 2024 Showing Benefit of Nadunolimab Combination Therapy in Cancer After Relapse on PD1-inhibitors | 476 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from two clinical trials of nadunolimab combination therapy... ► Artikel lesen | |
| 09.09. | Cantargia: New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors | 616 | ACCESSWIRE | LUND, SE / ACCESSWIRE / September 8, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported data from two clinical trials including nadunolimab combination therapy... ► Artikel lesen | |
| 28.08. | Cantargia Publishes Half-Year Report 2024 | 320 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / August 28, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for January to June 2024."It has been an... ► Artikel lesen | |
| 27.08. | Cantargia Reports Presentation of New Preclinical Data Supporting CAN10 in Fibrotic Lung Diseases | 270 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / August 27, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported presentation of new preclinical data providing support for CAN10 as... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 108,90 | -0,27 % | AT&S, BioNTech, Deutsche Bank, Kontron, Manz, Süss Microtec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 8,410 | +0,06 % | Evotec, Rheinmetall, Vidac Pharma Aktie: Kaufempfehlung, Krebsrevolution oder Kurseinbruch? | Das Potenzial auf eine Vervielfachung sehen Analysten bei der Aktie von Vidac Pharma. Der Wert gehört bereits zu den Überfliegern im Biotech-Sektor im zweiten Halbjahr. Das Unternehmen will die Krebsbehandlung... ► Artikel lesen | |
| QIAGEN | 43,015 | +0,27 % | PRESSESPIEGEL/Unternehmen: CONTINENTAL, QIAGEN, 1KOMMA5 GRAD, BOSCH, VOLKSBANKEN/SPARKASSEN | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
CONTINENTAL - Die Staatsanwaltschaft Hannover hat ihre Ermittlungsverfahren... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 685,60 | -0,20 % | Sanofi and Regeneron's Dupixent, Leo Pharma's Anzupgo could help close treatment gap in chronic hand eczema: GlobalData | ||
| BRAIN BIOTECH | 3,450 | +0,88 % | AKTIONÄR-Tipp BRAIN Biotech: Große Ziele - Neubewertung nimmt Fahrt auf | In den zurückliegenden Monaten hat sich die Aktie von BRAIN Biotech an der Börse eindrucksvoll zurückgemeldet. Und auch auf dem heutigen Kapitalmarkttag hat das Unternehmen mit Sitz im hessischen Zwingenberg... ► Artikel lesen | |
| SCORPIUS | 0,312 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model | DURHAM, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,212 | +0,83 % | Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Purchases 18,900 Shares of Stock | ||
| BURCON NUTRASCIENCE | 0,049 | -5,41 % | Burcon NutraScience Corporation: Burcon Updates Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| CSL | 168,46 | +0,26 % | Why CSL and these excellent ASX retirement shares could be buys in 2025 | ||
| MANNKIND | 6,448 | -4,22 % | MannKind stock up 10% amid bullish Wells Fargo note | ||
| OCULAR THERAPEUTIX | 8,068 | -1,99 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"), a biopharmaceutical company committed to improving vision in the real world through the development... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,586 | +1,28 % | Oxford Nanopore Technologies: Oxford Nanopore and UK Biobank to create world's first epigenetic dataset targeting the causes of cancer, dementia, complex disease | Pioneering research with potential to transform health outcomes through early detection, precise diagnoses, and personalised treatment for major diseases
Initiative will map the epigenome using... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,560 | -0,88 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK | Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down from... ► Artikel lesen | |
| CODEXIS | 4,644 | -1,90 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| TELO GENOMICS | 0,051 | -18,40 % | Telo Genomics Corp.: Telo Genomics Closes Oversubscribed $2.5 Million Private Placement | Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release... ► Artikel lesen |
CANTARGIA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,21 % bei einem Aktienkurs von 0,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.
